KOSDAQBiotech & Pharma298380

ABL Bio

₩36,150▼ 4.49%2026-11-18 close
Market Cap
₩2T
Turnover
₩10.4B
Volume
280K
Shares out.
56M
PER
—
PBR
14.8×
EPS
-₩1,503
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

ABL Bio: Platform Deal Flow Versus Clinical Risk

ABL Bio has built a large cumulative licensing record on its bispecific platforms, but after a key partnered trial missed in April 2026 its pipeline valuation is being reset, and reported results remain loss-making through Q3 2026.

  1. 1

    On reported figures, 2025 revenue was KRW 79.3 billion, up 137.6% from the prior year, and the operating loss narrowed to KRW 40.4 billion from KRW 59.4 billion in 2024.

  2. 2

    Reported results show losses in each of the last five quarters, from Q3 2025 through Q3 2026, and the controlling shareholders' net loss over the last four quarters totals KRW 81.9 billion.

  3. 3

    Cumulative licensing with global big pharma is reported at USD 6.5 billion, including the Eli Lilly platform deal signed in November 2025 with up to USD 2.602 billion in total value.

  4. 4

    In April 2026, a partner's failure to demonstrate an overall survival benefit for tovecimig (ABL001) sent the share price sharply lower, and the regulatory path and follow-on trials have since become the main variables.

  5. 5

    At the end of 2025 the debt ratio was 79.3%, total equity was KRW 156.7 billion, and operating cash flow was KRW -41.3 billion, so funding needs remain ongoing.

02

Business structure

ABL Bio is a bispecific-platform drug developer whose two core engines are Grabody-B, a blood-brain barrier shuttle, and Grabody-T, an immuno-oncology platform. Most of its licensing track record centers on Grabody-B.

Its deal with Eli Lilly, signed in November 2025, carries up to USD 2.602 billion in total value, and Lilly separately invested USD 15 million for an equity stake. Reported cumulative licensing with global big pharma is USD 6.5 billion.

The lead clinical assets are tovecimig (ABL001), developed with partner Compass Therapeutics for biliary tract cancer; givastomig (ABL111), co-developed with I-Mab, whose partner has since been reorganized as NovaBridBio, for gastric cancer; and next-generation bispecific ADCs (ABL206 and ABL209), with clinical Phase 1 work run by a U.S. subsidiary.

ABL105 and ABL104 were licensed to Yuhan. Revenue moves sharply with the timing of deal milestones, so the mix of income is lumpy.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.4B-₩22.4B−1552.8%
2025Q4₩0-₩29.7B—
2026Q1₩13.1B-₩17.2B−131.1%
2026Q2₩19.7B-₩16.8B−85.3%
2026Q3₩8.8B-₩19.9B−227.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩67.3B₩900M₩3.2B1.3%4.6%166.4%
2023₩65.5B-₩2.6B-₩2.6B−4.0%−3.6%116.2%
2024₩33.4B-₩59.4B-₩55.5B−177.8%−33.2%38.7%
2025₩79.3B-₩40.4B-₩37.8B−50.9%−24.4%79.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On reported annual figures, revenue fell from KRW 67.3 billion in 2022 to KRW 65.5 billion in 2023 (down 2.6% year on year) and then to KRW 33.4 billion in 2024 (down 49.0%), before rebounding to KRW 79.3 billion in 2025 (up 137.6%). Across 2022 to 2025, 2025 was the largest year and 2024 the smallest.

Operating profit of KRW 908 million in 2022 turned into an operating loss of KRW 2.62 billion in 2023, widened to KRW 59.4 billion in 2024, and narrowed to KRW 40.4 billion in 2025, which is three consecutive loss-making years from 2023 to 2025.

The operating margin moved from 1.3% in 2022 to -4.0% in 2023, -177.8% in 2024 and -50.9% in 2025. Net income attributable to controlling shareholders swung from KRW 3.21 billion in 2022 to a net loss of KRW 2.65 billion in 2023, then KRW 55.5 billion in 2024 and KRW 37.8 billion in 2025.

Net income including non-controlling interests, which is a different figure, was a net loss of KRW 37.9 billion in 2025. Operating cash flow went from KRW 72.1 billion in 2022 to KRW -28.4 billion in 2023, KRW -69.4 billion in 2024 and KRW -41.3 billion in 2025.

The debt ratio was 166.4% in 2022, 116.2% in 2023, 38.7% in 2024 and 79.3% in 2025. Quarterly revenue was KRW 1.44 billion in Q3 2025, KRW 13.1 billion in Q1 2026, KRW 19.7 billion in Q2 2026 (up 50.0% quarter on quarter) and KRW 8.76 billion in Q3 2026 (down 55.6% quarter on quarter, but up 506.8% year on year).

No Q4 2025 revenue data is available. Operating losses were KRW 22.4 billion in Q3 2025, KRW 29.7 billion in Q4 2025, KRW 17.2 billion in Q1 2026, KRW 16.8 billion in Q2 2026 and KRW 19.9 billion in Q3 2026. The swings in quarterly revenue suggest that the timing of deal recognition has a large effect.

05

Industry analysis

A January 2026 read-through from the J.P. Morgan Healthcare Conference was that global pharma companies are increasingly seeking assets with a real chance of clinical success rather than platforms alone, which favors companies with clinical data but also means a trial setback can quickly reduce pipeline value.

Bispecific ADCs are generally regarded as offering better safety and efficacy than single-antigen ADCs because they target two antigens at once. Among listed Korean biotech peers, LigaChem Biosciences is the closest comparison for ADC-based licensing, and Alteogen is a reference point for platform-fee models.

ABL Bio's distinguishing point is that its blood-brain barrier shuttle has been tested in several deals with large pharma companies.

Kiwoom Securities, in an April 2026 note, described a 64% share price drop on April 27 after the partner failed to prove an overall survival benefit for tovecimig, and expected an accelerated approval process after a pre-BLA meeting with the FDA.

The sector is currently reacting strongly to clinical and regulatory news. Yuhan's licensing of ABL105 and ABL104 shows that domestic pharma companies also take part as partners in the platform ecosystem.

06

Outlook

The key checkpoint is the regulatory path for tovecimig. Reports say the company plans to complete the ongoing Phase 2 trial in consultation with the FDA and enter a pivotal Phase 3 trial by the end of 2026.

The plan was formed after the April 2026 setback on overall survival, so whether the Phase 3 start happens will shape pipeline value. For givastomig (ABL111), reported Phase 1b objective response rates were 77% at 8 mg/kg and 73% at 12 mg/kg, with median progression-free survival of 16.9 months.

In next-generation ADCs, the Phase 1 IND for ABL209 is scheduled for early next year, and initial clinical data for the two ADC candidates are planned for public release in 2027. In immuno-oncology, ABL503 is in Phase 1 and the company has received approval to expand its Phase 1 scope.

Because quarterly revenue depends on new licensing deals, future contract disclosures are the main input for revenue expectations. The full-year 2026 results will be confirmed in the annual report, which is the next regular filing.

07

Valuation

PER
—
PBR
14.8×
ROE
-50.4%
EPS
-₩1,503
BPS
₩2,557
Dividend per share
₩0

Because the company is in a net-loss stretch over the last four quarters, a price-to-earnings multiple cannot be calculated.

On a book-value basis, the price-to-book ratio sits at a large premium to net assets within the sector, which suggests the market is pricing pipeline and platform deal value well above the balance-sheet equity.

Controlling shareholders' equity was KRW 154.7 billion at the end of 2025, and total equity was KRW 156.7 billion. The dividend yield is at a level that implies no shareholder payout, so it is low against the sector average.

Brokers have typically valued the platform separately and added it to the target-value build; for example, Kyobo Securities in November 2025 raised its platform value estimate for Grabody-B. After the April 2026 trial setback, several brokers adjusted pipeline values downward to reflect the result.

The main valuation variables are the regulatory path for tovecimig, the clinical progress of givastomig, and new platform deals.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Cumulative licensing and big pharma ties

Reported cumulative licensing reaches USD 6.5 billion. The November 2025 Eli Lilly deal carries up to USD 2.602 billion in total value, and Lilly also made an equity investment. A January 2026 upfront payment disclosure shows that platform deals have produced actual cash receipts.

Breadth of the clinical pipeline

The company is reported to have eight bispecific candidates in clinical development, spanning biliary tract cancer, gastric cancer, next-generation ADCs and immuno-oncology. Givastomig reported objective response rates in the 70% range or higher at both tested doses in Phase 1b. Initial data for the ADC candidates are planned for 2027.

Narrowing losses

The operating loss narrowed from KRW 59.4 billion in 2024 to KRW 40.4 billion in 2025. Q3 2026 revenue of KRW 8.76 billion was up 506.8% year on year, and the operating loss of KRW 19.9 billion was smaller than the KRW 22.4 billion a year earlier. Quarterly results remain volatile, but the loss scale has shrunk compared with earlier periods.

09

Bear factors

Failed overall survival proof in a key trial

In April 2026, the partner Compass Therapeutics did not clearly prove an overall survival benefit for tovecimig. The share price fell sharply in the wake of that result. Whether the program moves toward accelerated approval depends on the outcome of discussions with the FDA, and the uncertainty remains high.

Continued losses and cash outflow

Losses have continued, and cash has also flowed out of operations. Operating cash flow was KRW -41.3 billion in 2025. Without a clear timetable for a return to profit, funding pressure could persist.

Revenue dependent on one-off deal income

Quarterly revenue fell from KRW 19.7 billion in Q2 2026 to KRW 8.76 billion in Q3 2026, a 55.6% drop quarter on quarter. When revenue depends on the timing of upfront payments and milestones, quarterly results are hard to forecast. There is no reported revenue figure for Q4 2025, which makes the trend harder to trace.

10

Risk factors

Clinical and regulatory risk

It is not yet settled whether tovecimig will go down an accelerated approval path or face additional trial requirements. Givastomig and the ADC candidates also cannot be judged until clinical data are released. Delays in trial timelines could also push back milestone recognition from licensing deals.

Partner dependence risk

Several core pipeline assets are developed under partner leadership, so changes in partner strategy directly affect the company's value. Givastomig is developed with NovaBridBio, the successor to the I-Mab partnership, and tovecimig depends on the regulatory strategy of Compass Therapeutics. If partners change their clinical judgments, the company's timelines may change as well.

Financial structure risk

Total liabilities at the end of 2025 were KRW 124.2 billion, and the debt ratio was 79.3%, up from 38.7% in 2024. Whether the company borrows or raises capital will shape the financial burden. With operating cash outflows continuing, repeated capital raises would also raise the question of shareholder dilution.

11

What to watch next

  1. Late December 2026 (per company plan)

    Whether the pivotal Phase 3 trial for tovecimig starts as planned. It will show whether the regulatory path has moved forward after the overall survival setback.

  2. After year-end 2026 (as disclosed)

    New licensing agreements and upfront payment disclosures. They will show whether quarterly revenue swings come from deal recognition.

  3. By late March 2027 (annual report deadline)

    The 2026 annual report, when full-year 2026 revenue, operating loss, cash flow and Q4 results become reported figures.

  4. 2027 (per company plan)

    Planned release of initial clinical data for ABL206 and ABL209, the first readout for the next-generation ADC pipeline.

12

Overall view

ABL Bio has grown its cumulative licensing total through bispecific platform deals, and on reported figures 2025 revenue rose to KRW 79.3 billion while the operating loss narrowed to KRW 40.4 billion.

However, losses have continued across five consecutive quarters from Q3 2025 through Q3 2026, and the controlling shareholders' net loss over the last four quarters totals KRW 81.9 billion. The April 2026 overall survival setback for tovecimig remains the largest variable for pipeline value.

Bullish factors include cumulative deal size, the breadth of the clinical pipeline and the narrowing loss scale. Bearish factors include clinical uncertainty, partner dependence, cash outflows and a revenue base dependent on one-off deal income.

With no earnings-based multiple available, the valuation rests on a large premium to net assets and is sensitive to pipeline outcomes. The next checkpoints are the planned Phase 3 start for tovecimig by year-end 2026, new licensing disclosures, and the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. docdocdoc.co.kr
  2. ablbio.com
  3. press9.kr
  4. ablbio.com
  5. infotoday.kr
  6. m.irgo.co.kr
  7. moneytoring.ai
  8. gazet.ai
  9. news.nate.com
  10. newspim.com
  11. news.nate.com
  12. newspim.com
  13. newspim.com
  14. news.nate.com
  15. m.news.nate.com
  16. alphadistill.com
  17. needinfo.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis